Literature DB >> 7018145

The effects of cyproheptadine on glucose tolerance and pancreatic islets in rats.

R Kikkawa, D Duvillard, W Stauffacher.   

Abstract

The effects of cyprohepatadine (CPH) on plasma levels, of glucose, insulin and glucagon were studied in rats in order to clarify the diabetogenicity of this compound. CPH was given to the rats at a daily dose of 45 mg per kg body weight via gastric intubation for up to 20 days. Glucose intolerance appeared after 5 days of CPH treatment without significant increase in fasting glucose level. Plasma insulin response to glucose loading was depressed in the early phase of the glucose tolerance test in groups treated for 10 and 20 days. In these groups the insulinogenic index was significantly lowered. Pancreatic insulin content decreased rapidly after single dose of CPH. Plasma level and pancreatic content of glucagon were not changed by this compound. These results suggested that chronic treatment with CPH caused glucose intolerance in rats through its direct influence on pancreatic B-cell function.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018145     DOI: 10.1007/bf02098995

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  11 in total

1.  Ultrastructural study of alterations in beta cells of pancreatic islets from cyproheptadine-treated rats.

Authors:  D S Longnecker; J S Wold; L J Fischer
Journal:  Diabetes       Date:  1972-02       Impact factor: 9.461

2.  Species dependent pancreatic islet toxicity produced by cyproheptadine: alterations in beta cell structure and function.

Authors:  J S Wold; D S Longnecker; L J Fischer
Journal:  Toxicol Appl Pharmacol       Date:  1971-06       Impact factor: 4.219

3.  Quantitative and qualitative aspects of islet function in the rat.

Authors:  W J Malaisse; F Malaisse-Lagae; S King
Journal:  J Lab Clin Med       Date:  1968-01

4.  The tissue distribution of cyproheptadine and its metabolites in rats and mice.

Authors:  J S Wold; L J Fischer
Journal:  J Pharmacol Exp Ther       Date:  1972-10       Impact factor: 4.030

5.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

6.  Effects of cyproheptadine on insulin secretion by isolated perifused rat islets.

Authors:  B P Richardson; M L McDaniel; P E Lacy
Journal:  Diabetes       Date:  1975-09       Impact factor: 9.461

7.  Inhibition o'f insulin release by cyproheptadine: effects on 3',5'-cyclic-AMP-content and 45Ca-accumulation of incubated mouse islets.

Authors:  H G Joost; J Beckmann; S Lenzen; A Hasselblatt
Journal:  Acta Endocrinol (Copenh)       Date:  1976-05

8.  The effect of cyproheptadine on carbohydrate metabolism.

Authors:  A Drash; J Elliott; H Langs; A F Lavenstein; R E Cooke
Journal:  Clin Pharmacol Ther       Date:  1966 May-Jun       Impact factor: 6.875

9.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus.

Authors:  H S Seltzer; E W Allen; A L Herron; M T Brennan
Journal:  J Clin Invest       Date:  1967-03       Impact factor: 14.808

10.  Inhibition of insulin and glucagon release from the perfused rat pancreas by cyproheptadine (Periactinol, Nuran).

Authors:  H G Joost; J Beckmann; S Holze; S Lenzen; W Poser; A Hasselblatt
Journal:  Diabetologia       Date:  1976-07       Impact factor: 10.122

View more
  1 in total

1.  The effect of cyproheptadine on insulin biosynthesis.

Authors:  R Kikkawa; D Duvillard; W Stauffacher
Journal:  Experientia       Date:  1985-01-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.